{"type":"trials","record":{"id":36133,"source_id":"clinicaltrials-gov","external_id":"NCT05263596","title":"SARCOPEDIA - Sarcopenia Diagnostics in Aging Medicine","brief_summary":"Musculoskeletal aging is one of the major responsibilities and challenges for public health. In particular, sarcopenia correlates with an increased risk of falls and increased morbidity and mortality. With regard to screening for sarcopenia, the guidelines of the European Working Group on Sarcopenia in Older People (EWGSOP2) refer to algorithmic case finding, diagnosis, and quantification of the severity of sarcopenia in clinical. While functional measurements are more difficult to standardize and associated with higher variability, Dual-energy X-ray absorptiometry (DXA) is considered a highly accurate method, even referred to as the \"gold standard\" to determine muscle mass in the scientific literature. Nevertheless, DXA, which is routinely used, shows inconsistent correlation with functional decline in muscle strength. Another method of muscle quantification is bioelectrical impedance analysis (BIA), a simple, portable instrument that is more readily available and applicable due to its lower cost. However, it tends to overestimate muscle mass and is also more susceptible to a person's hydration status. Because of these difficulties, recent research has focused on the potential of using shear wave elastography. This method indirectly serves to quantify the rapid type II muscle fibers in order to make statements about the muscle quality because an age-related decrease in type II muscle fibers is associated with a more frequent fall frequency. First, the investigators will define three different categories according to the EWGSOP 2 guidelines based on the muscle strength (grip strength, assessed by pneumatic hand dynamometer) and muscle mass (Appendicular skeletal muscle mass, assessed by BIA): \"No Sarcopenia\", \"Probable Sarcopenia\" and \"Confirmed Sarcopenia\". Within these categories, the Investigators would like to establish a multivariate data analysis of different functional measurements with quantitative imaging results. This exploratory trial design is intended to improve understanding within the three categories and to test proxy measurements of different patients who are ruled out for common routine measurements due to, for example, cognitive impairment or pre-existing rheumatic disease. This is essential to consider the heterogeneity of the aging society proportionally.","overall_status":"Unknown","phases":[],"study_type":"INTERVENTIONAL","sponsor":"University Department of Geriatric Medicine FELIX PLATTER","enrollment":120,"countries":["Switzerland"],"start_date":"2022-07-11","completion_date":"2024-10-30","last_update_date":"2024-07-18","source_url":"https://clinicaltrials.gov/study/NCT05263596","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:24.196666+00:00","last_seen_at":"2026-09-25T06:10:25.747+00:00","metadata":{"sex":"ALL","acronym":"SARCOPEDIA","age_range":"65 Years","comparator":null,"organization":"University Department of Geriatric Medicine FELIX PLATTER","interventions":["dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound"],"registry_source":"ClinicalTrials.gov","outcome_measures":["No Sarcopenia (healthy participants) - according to the current European Working Group on Sarcopenia in Older People 2…","Probable Sarcopenia - according to the current European Working Group on Sarcopenia in Older People 2 — 12 months","Confirmed Sarcopenia - according to the current European Working Group on Sarcopenia in Older People 2 — 12 months"],"design_description":"NON RANDOMIZED · CROSSOVER · PREVENTION · SINGLE","source_has_results":false},"controlled_terms":["Sarcopenia","Muscle Weakness","Frailty","dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: sarcopenia.","quality_checked_at":"2026-09-25T06:10:37.875473+00:00","duplicate_cluster_key":"id:nct05263596","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-07-11 to 2024-10-30","comparator":null,"confidence":"structured-source","population":"ALL · 65 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:10:25.844Z","intervention":["dual x-ray absorptiometry, body impedance analysis, muscle strength measurements, ultrasound"],"participants":120,"study_design":"NON RANDOMIZED · CROSSOVER · PREVENTION · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["No Sarcopenia (healthy participants) - according to the current European Working Group on Sarcopenia in Older People 2…","Probable Sarcopenia - according to the current European Working Group on Sarcopenia in Older People 2 — 12 months","Confirmed Sarcopenia - according to the current European Working Group on Sarcopenia in Older People 2 — 12 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"sarcopenia","is_published":true,"match_reasons":["Title contains controlled term: sarcopenia.","Abstract contains controlled term: sarcopenia.","Source terminology contains: sarcopenia.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Sarcopenia","slug":"sarcopenia"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/36133","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}